by Rhoda Wilson, Expose News:
A response to a freedom of information request, which in New Zealand is called an Official Information Act (“OIA”) request, showing chest pain and cardiac incidences in younger people has brought mixed responses from New Zealanders, most displaying an underlying sense of incredulity.
“Making sense of the scale of the disaster is hard,” Dr. Guy Hatchard says. But “the OIA data for chest pain and cardiac events is not an isolated statistic.”
TRUTH LIVES on at https://sgtreport.tv/
A follow-up survey of New Zealanders who had been diagnosed with mRNA vaccine-induced myopericarditis was conducted by Health New Zealand and, after delaying publishing the survey results for two years, the results were published this month.
The lack of information has had the effect of myopericarditis being greatly underdiagnosed or a diagnosis and clinical response delayed, even in some cases for years. Yet, this information deficit continues to this day.
“Well over 30,000 people [ ] will report to Accident and Emergency with chest pains this year, compared to just 2,000 pre-pandemic,” Dr. Hatchard says.
Medsafe Report Underlines the Ongoing Myocarditis Crisis
By Dr. Guy Hatchard, 27 September 2024
The extraordinary New Zealand data on chest pain and cardiac incidence among the under-forties, which has increased tenfold and remains high right up to the present, has provoked many questions and comments in our email inbox. Ranging from, “How could the authorities let this happen” to the ridiculous, “The OIA doesn’t exist” and everything in between. Making sense of the scale of the disaster is hard, and facing up to the failure and duplicity of those charged with protecting our health is even more perplexing.
The OIA data for chest pain and cardiac events is not an isolated statistic. Medsafe has just released the results of a follow-up survey of 298 New Zealand patients who received a clinical diagnosis of mRNA vaccine-induced myopericarditis at least 90 days prior to filling in the survey. This survey was conducted two years ago. Inexplicably, Medsafe has waited until now to release the results. Contrary to earlier advice given to people experiencing symptoms of myocarditis that the final outcome would be mild and self-limiting, the survey revealed persistent serious problems beyond 90 days which had not been resolved.
The median age was 36.5 years. 62% were male…. Chest pain was the most frequently reported physical symptom, experienced by 287 (96.3%) participants, followed by fatigue (256; 85.9%), shortness of breath (251; 84.2%), palpitations (234; 78.5%), and dizziness (189; 63.4%). Twenty-two (7.4%) participants reported fainting.
Long-term outcomes of myocarditis and pericarditis following vaccination with Comirnaty (Pfizer/BioNTech COVID-19 vaccine), A survey of adolescents, adults, and their healthcare professionals in Aotearoa New Zealand, September 2024, pg. 16
Representative survey responses to a range of open-ended questions about work, family life, treatment, follow-up, etc included the following:
“Tried to exercise again and pericarditis symptoms returned.”
“Chest pain is extreme … not being able to walk without a cane.”
“This experience has caused anxiety and depression.”
“Before I was diagnosed, I was a full-time worker and into [sporting activity], since I got it, I can’t work at all or do any exercise.”
“Not being able to take care of my children is just awful. I can’t even kick a ball with my sons anymore.”
“I was initially told a number of times in ED [emergency department] that I was having anxiety attacks. I felt like no one was listening to me which made it even harder.”
“Was anxious about having the booster and I was fobbed off. I am not an ‘anti-vaxxer’. Doctors need to listen and be more empathetic.”
“Disappointed with lack of aftercare. Absolutely no specialist follow-up. Very disappointing.”
“Utter frustration that I had to go privately to get any help. Was told it would take one year to get any cardiac test. I would still be waiting for a diagnosis. I had to go privately.”
“To hear … myopericarditis repeatedly being reported as a mild consequence of vaccination was a huge insult and should immediately stop. This is not a mild sequela for many. This is a profound life-changing and devastating event.”
“ACC – although accepting my vaccine injury treatment injury claim – decided seven days was sufficient time to recover [from it] … it took … nearly 8 months after the claim, for full cover to be approved.”
Long-term outcomes of myocarditis and pericarditis following vaccination with Comirnaty (Pfizer/BioNTech COVID-19 vaccine), A survey of adolescents, adults, and their healthcare professionals in Aotearoa New Zealand, September 2024, pg. 19
The ‘Key Learnings’ section of the report admits there were deficiencies in:
- The vaccine information given to the public.
- Reporting systems for adverse reactions.
- Knowledge about possible adverse reactions.
- Keeping up to date with the implications of clinical publishing.
The net effect was to create a deficient clinical and informational response to the tens of thousands of people reporting to GPs and emergency departments with chest pain. As a result, myopericarditis has been greatly underdiagnosed or a diagnosis and clinical response have been delayed, even in some cases for years.
